Skye Bioscience, Ownership
| SKYE Stock | USD 2.85 0.01 0.35% |
Shares in Circulation | First Issued 2018-06-30 | Previous Quarter 38.7 M | Current Value 38.8 M | Avarage Shares Outstanding 332 M | Quarterly Volatility 338.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Skye |
Skye Stock Ownership Analysis
About 85.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.14. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Skye Bioscience, Common recorded a loss per share of 3.6. The entity had not issued any dividends in recent years. The firm had 1:250 split on the 8th of September 2023. Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California. Skye Bioscience operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 9 people. To find out more about Skye Bioscience, Common contact the company at 858 410 0266 or learn more at https://skyebioscience.com.Besides selling stocks to institutional investors, Skye Bioscience, also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Skye Bioscience,'s stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Skye Bioscience,'s strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Skye Bioscience, Quarterly Liabilities And Stockholders Equity |
|
Skye Bioscience, Insider Trades History
Only 1.89% of Skye Bioscience, Common are currently held by insiders. Unlike Skye Bioscience,'s institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Skye Bioscience,'s private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Skye Bioscience,'s insider trades
Skye Bioscience, Common Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Skye Bioscience, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Skye Bioscience,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Skye Bioscience, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schwab Andrew J. over a week ago Insider Trading | ||
Grayson Paul A. over a month ago Disposition of 307 shares by Grayson Paul A. of Skye Bioscience, at 5.55 subject to Rule 16b-3 | ||
Dhillon Punit over a month ago Acquisition by Dhillon Punit of 110000 shares of Skye Bioscience, at 0.0171 subject to Rule 16b-3 | ||
Jenkins Annalisa over a month ago Acquisition by Jenkins Annalisa of 70000 shares of Skye Bioscience, at 5.15 subject to Rule 16b-3 | ||
5am Partners Vii, Llc over three months ago Disposition of tradable shares by 5am Partners Vii, Llc of Skye Bioscience, at 6.06 subject to Rule 16b-3 | ||
5am Partners Vii, Llc over three months ago Disposition of 1440 shares by 5am Partners Vii, Llc of Skye Bioscience, at 6.6 subject to Rule 16b-3 |
Skye Bioscience, Outstanding Bonds
Skye Bioscience, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Skye Bioscience, Common uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Skye bonds can be classified according to their maturity, which is the date when Skye Bioscience, Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| SWKS 3 01 JUN 31 Corp BondUS83088MAL63 | View | |
| SWKS 18 01 JUN 26 Corp BondUS83088MAK80 | View | |
| US830867AB33 Corp BondUS830867AB33 | View |
Skye Bioscience, Corporate Filings
| 19th of December 2024 Other Reports | ViewVerify | |
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.